0000000000769195

AUTHOR

Urs O. Häfeli

showing 3 related works from this author

Continuously manufactured magnetic polymersomes--a versatile tool (not only) for targeted cancer therapy.

2013

Micromixer technology was used to prepare polymeric vesicles (Pluronic® L-121) dual loaded with the anti-cancer drug camptothecin and magnetic nanoparticles. Successful incorporation of the magnetic nanoparticles was confirmed by transmission electron microscopy. Dynamic light scattering measurements showed a relatively narrow size distribution of the hybrid polymersomes. Camptothecin polymersomes reduced the cell viability of prostate cancer cells (PC-3) measured after 72 h significantly, while drug-free polymersomes showed no cytotoxic effects. Covalent attachment of a cancer targeting peptide (bombesin) as well as a fluorescent label (Alexa Fluor® 647) to the hybrid polymersomes was perf…

BiodistributionRelaxometryMaterials scienceCell SurvivalMicromixerNanotechnologyAntineoplastic AgentsPoloxamerlaw.inventionPolyethylene GlycolsConfocal microscopylawCell Line TumorNeoplasmsmedicineHumansGeneral Materials SciencePrecision MedicineMagnetite NanoparticlesDrug CarriersCarbocyaninesPropylene GlycolsDrug deliveryPolymersomeMagnetic nanoparticlesBombesinCamptothecinCamptothecinmedicine.drugNanoscale
researchProduct

Multifunctional nanocarriers for biomedical applications

2013

Polymeric vesicles (Pluronic ® L-121) loaded with magnetic nanoparticles (MNP) and an anti-cancer drug (camptothecin) were prepared continuously in a micro mixing device. Characterization by TEM confirmed the successful incorporation of the MNP and DLS measurements showed a relatively narrow size distribution of the hybrid polymersomes. A very high drug loading of camptothecin (100 μg/ml in the polymersome formulation) was reached and a drug release study of loaded magnetic polymersomes has shown a sustained camptothecin release over several days. Carboxylation of Pluronic ® L-121 was performed and enabled a further surface functionalization with bombesin, a 14 amino acid peptide, which bin…

ChemistryPolymersomeDrug deliverymedicineGastrin-releasing peptide receptorBiophysicsNanotechnologyNanocarriersPoloxamerPreclinical imagingCamptothecinmedicine.drugAlexa FluorColloidal Nanocrystals for Biomedical Applications VIII
researchProduct

On the consensus nomenclature rules for radiopharmaceutical chemistry – Reconsideration of radiochemical conversion

2021

Radiochemical conversion is an important term to be included in the "Consensus nomenclature rules for radiopharmaceutical chemistry". Radiochemical conversion should be used to define reaction efficiency by measuring the transformation of components in a crude reaction mixture at a given time, whereas radiochemical yield is better suited to define the efficiency of an entire reaction process including, for example, separation, isolation, filtration, and formulation. (C) 2020 Elsevier Inc. All rights reserved.

Cancer ResearchRadiochemistryNomenclatureRadiochemical conversionChemistryRadiochemistry610 Medicine & health10181 Clinic for Nuclear MedicineTerminology030218 nuclear medicine & medical imagingNuclear chemistryRadiochemical yield03 medical and health sciences0302 clinical medicineddc:5701313 Molecular Medicine030220 oncology & carcinogenesisYield (chemistry)2741 Radiology Nuclear Medicine and ImagingMolecular Medicine1306 Cancer ResearchRadiology Nuclear Medicine and imagingRadiopharmaceutical sciencesConsensus guidelinesNuclear Medicine and Biology
researchProduct